Evidence map›Paper›PMID 37888291›Full record

ArticleJournal of fungi (Basel, Switzerland)2023

Evaluation of Antifungal Selective Toxicity Using

Keiko Nakano, Michiyo Okamoto, Azusa Takahashi-Nakaguchi, Kaname Sasamoto, Masashi Yamaguchi, Hiroji Chibana

Open access · goldAbstract read
In one paragraph

Article in Journal of fungi (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Keiko NakanoMedical Mycology Research Center, Chiba University, Chiba 260-8673, Japan.ORCID 0009-0006-8952-9171
Michiyo OkamotoMedical Mycology Research Center, Chiba University, Chiba 260-8673, Japan.ORCID 0000-0003-4280-6048
Azusa Takahashi-NakaguchiMedical Mycology Research Center, Chiba University, Chiba 260-8673, Japan.ORCID 0000-0002-6652-4654
Kaname SasamotoMedical Mycology Research Center, Chiba University, Chiba 260-8673, Japan.
Masashi YamaguchiMedical Mycology Research Center, Chiba University, Chiba 260-8673, Japan.
Hiroji ChibanaMedical Mycology Research Center, Chiba University, Chiba 260-8673, Japan.ORCID 0000-0002-3400-5569
Chiba University Hospital · JPUniversity of the Ryukyus · JP

Funding

AMED JP22nk0101553AMED JP23fk0108679National Bio-Resource Project Japan NA
6 · The paper itself

Abstract

With only four classes of antifungal drugs available for the treatment of invasive systemic fungal infections, the number of resistant fungi is increasing, highlighting the urgent need for novel antifungal drugs. Ergosterol, an essential component of cell membranes, and its synthetic pathway have been targeted for antifungal drug development. Sterol-C4-methyl monooxygenase (Erg25p), which is a greater essential target than that of existing drugs, represents a promising drug target. However, the development of antifungal drugs must consider potential side effects, emphasizing the importance of evaluating their selective toxicity against fungi. In this study, we knocked in

Indexed as

antimicrobial resistance (AMR)C4-methyl sterol oxidaseC. albicansC. parapsilosisdrug resistantmethylsterol monooxygenase 1 (MSMO1)molecular target drugnon-albicans Candida (NAC)specific inhibitorstealth infection

Identifiers

PMID37888291
PMCPMC10607794
OpenAlexW4387809223

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.